kidney

Advertisement
Charlotte RobinsonCOVID-19 and Kidney Disease | July 14, 2025
Research showed a link between SARS-CoV-2 infection and greater CKD risks and other kidney outcomes.
Charlotte RobinsonIgA Nephropathy | June 26, 2025
We spoke with George Edward Newman, MD, a site principal investigator of the PREVAIL study of felzartamab in IgAN.
Charlotte RobinsonChronic Kidney Disease | June 19, 2025
Kidney Care Partners visited called on Congress to support policies benefitting Americans with kidney disease.
Charlotte RobinsonDiabetes and Hypertension | June 18, 2025
Meta-analyses reaffirmed cardiovascular and renal benefits of long-acting GLP-1RAs for patients with type 2 diabetes.
Charlotte RobinsonNephrology Times | June 14, 2025
A report based on chart data and specialist surveys reveals gaps in treatment for FSGS but optimism about the drug pipeline.
Charlotte RobinsonNephrology Times | June 13, 2025
The FDA has granted Orphan Drug Designation to veverimer for anti–glomerular basement membrane (anti-GBM) disease.
Richard Furie, MDNephrology Times | June 26, 2025
Richard Furie, MD, discussed the REGENCY trial of obinutuzumab in systemic lupus erythematosus and lupus nephritis.
Victoria SochaGout | June 26, 2025
Gene sequencing of a patient with gouty sacroiliitis and gouty nephropathy highlighted genetic factors leading to gout.
Charlotte RobinsonERA Congress 2025 | July 7, 2025
Pegcetacoplan reduced proteinuria and stabilized eGFR in adolescent patients with C3G or primary IC-MPGN.
Charlotte RobinsonERA Congress 2025 | June 11, 2025
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3G/IC-MPGN and nephrotic range proteinuria.
Victoria SochaIgA Nephropathy | July 2, 2025
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
Charlotte RobinsonERA Congress 2025 | June 26, 2025
Researchers identified three immune phenotypes of checkpoint inhibitor-induced acute interstitial nephritis.
Victoria SochaIgA Nephropathy | June 5, 2025
Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.
Victoria SochaEnd-Stage Renal Disease | June 26, 2025
Hemodialysis patients reporting shorter sleep or problems sleeping had a higher mortality risk in an observational study.
Victoria SochaChronic Kidney Disease | July 7, 2025
Finerenone had kidney and cardiovascular benefits for patients with CKD even after an acute eGFR change occurred.
Victoria SochaNephrology Times | June 26, 2025
Higher cardiovascular mortality risk was associated with higher CKM syndrome stage, research showed.
Charlotte RobinsonNephrology Times | May 29, 2025
The Annual Global Summit on Kidney Disease Innovations included sessions on rare diseases, human organ alternatives, and more
Victoria SochaChronic Kidney Disease | June 26, 2025
A dual SGLT inhibitor may have ischemic benefits for patients with CKD, T2D, and cardiovascular risks, a study found.
Victoria SochaChronic Kidney Disease | June 26, 2025
An analysis of CKD trials supported 3-year total slope as the primary slope-based outcome in randomized trials.
Victoria SochaNephrology Times | June 26, 2025
Cyclophosphamide-rituximab therapy and minimal use of glucocorticoids in ANCA-associated vasculitis may reduce morbidity.
Advertisement